Aravive’s batiraxcept was granted orphan designation by the FDA in the treatment of pancreatic cancer, according to a post to the agency’s website.Reference Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ARAV:
- 2 “Strong Buy” Penny Stocks With Multibagger Potential
- Aravive to Present Positive Updated Data from Phase 1b Trial of Batiraxcept in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma at the 2023 ASCO Genitourinary (GU) Cancers Symposium
- Aravive to present positive updated data from ph1 trial of Batiraxcept at ASCO
- Aravive initiated with a Buy at EF Hutton
- Aravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer